Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group HoldingsASX:TRJ -11.71%38 3-Year ROIIC % is 1.78 as of Jun. 2025, which is 68% above its 10-year median of 1.06. GuruFocus rates ASX:TRJ with a GF Score™ of 38/100 and a GF Value™ of A$1.11 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 796 Medical Devices & Instruments companies, Trajan Group Holdings ranks better than 50.13% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Trajan Group Holdings's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 1.78%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Trajan Group Holdings's 3-Year ROIIC % or its related term are showing as below:
ASX:TRJ's 3-Year ROIIC % is ranked better than 50.13% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 1.62
vs ASX:TRJ: 1.78
Trajan Group Holdings (ASX:TRJ) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Trajan Group Holdings 3-Year ROIIC % Related Terms
Trajan Group Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Trajan Group Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:TRJ vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's 3-Year ROIIC % falls into.
Trajan Group Holdings's 3-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 3.485 (Jun. 2025) - 4.2575406 (Jun. 2022) )
/
( 163.269 (Jun. 2025) - 206.685 (Jun. 2022) )
=
-0.7725406
/
-43.416
=
1.78%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Trajan Group Holdings (ASX:TRJ) has a 3-Year ROIIC % of 1.78 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Trajan Group Holdings and its competitors. This is 68% above median its historical median of 1.06. Over the past decade, Trajan Group Holdings' 3-Year ROIIC % has ranged from 0.33 to 1.78. According to the industry distribution chart, Trajan Group Holdings ranks #397 out of 796 companies in the Medical Devices & Instruments industry, placing it in the top 49.9%.
Is Trajan Group Holdings' 3-Year ROIIC % too high?
Trajan Group Holdings' current 3-Year ROIIC % of 1.78 is 68% above median its 10-year median of 1.06. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 1.78. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.62. Trajan Group Holdings' value of 1.78 is 9.9% above this industry median. Based on the distribution chart, Trajan Group Holdings ranks #397 out of 796 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Trajan Group Holdings has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Trajan Group Holdings ranks #397 out of 796 companies for 3-Year ROIIC %. This puts Trajan Group Holdings in the upper half of its industry. The industry median 3-Year ROIIC % is 1.62. Trajan Group Holdings' value of 1.78 is 9.9% above this benchmark. Historically, Trajan Group Holdings' own 3-Year ROIIC % has ranged from 0.33 to 1.78 over the past decade. While the company's 10-year median is 1.06 vs. the industry median of 1.62, Trajan Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.62, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trajan Group Holdings's current 3-Year ROIIC % of 1.78 is 9.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Trajan Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trajan Group Holdings's current 3-Year ROIIC % is 1.78, which is 68% above median its own 10-year median of 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Trajan Group Holdings (ASX:TRJ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.11, compared to a current price of A$0.25 — trading 77.9% below its estimated fair value. The current 3-Year ROIIC % is 1.78, which is 68% above median its 10-year median of 1.06 and 9.9% above the Medical Devices & Instruments industry median of 1.62. Trajan Group Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Trajan Group Holdings (ASX:TRJ), the current 3-Year ROIIC % is 1.78 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (ASX:TRJ) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of A$0.25 is trading 77.9% below its estimated GF Value™ of A$1.11.
GuruFocus considers Trajan Group Holdings to be Possible Value Trap.
Key valuation signals for ASX:TRJ:
3-Year ROIIC %: 1.78 (68% above median its 10-year median of 1.06)
GF Value™: A$1.11 vs. price of A$0.25 (77.9% below fair value)
Industry Position: 9.9% above the Medical Devices & Instruments median (#397 of 796)
No single metric tells the full story. See the ASX:TRJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
38GF Score
Get the complete analysis for ASX:TRJ
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRJ has been successfully added to your 
